UpdatesPress Release
OneSource reports strong Q1FY27 results: Revenue ₹449.0 Cr (+37% YoY), EBITDA ₹123.3 Cr (+39% YoY), PAT ₹63.7 Cr (+72% YoY). Growth driven by semaglutide launch & new client wins.
Onesource Specialty Pharma LimitedONESOURCE · Filed with the exchange
Second cartridge line commercializing Q2; biologics pipeline growing.
FY28 guidance of $400M organic revenue reaffirmed.
No comments yet. Be the first.